Our Firm is representing a number of clients in Stryker hip lawsuits who have made claims similar to those put forth by the Florida plaintiffs. We will be monitoring this matter very closely.
New York, New York (PRWEB) July 15, 2014
Stryker hip lawsuits (http://www.strykerhiprecallclaims.com/) filed in the wake of the 2012 recall of Rejuvenate and ABG II Modular-Neck Hip Stems continue to move forward in litigations throughout the U.S., Bernstein Liebhard LLP reports. According to a Motion filed July 1, 2014 in Florida’s Broward County Circuit Court, a number of Stryker hip recall plaintiffs are seeking an Order that would compel Stryker to disclose adverse event information relating to similar products, including studies and analysis of modular hip systems that they say formed the basis of the company’s 510(k) application for regulatory clearance of the Rejuvenate Hip System. According to the Motion, Stryker has thus far refused to provide the information, which plaintiffs contend is considered standard form in drug and medical device litigation. (In Re: Rejuvenate and ABG II Modular Hip Implant Litigation, No. 14-90000)
“Our Firm is representing a number of clients in Stryker hip lawsuits who have made claims similar to those put forth by the Florida plaintiffs. We will be monitoring this matter very closely,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to offer free legal evaluations to individuals were allegedly harmed by Stryker’s Rejuvenate and ABG II Modular-Neck Hip Stems.
Stryker Hip Recall
The Stryker hip recall was announced by the U.S. Food & Drug Administration (FDA) on July 6, 2012, after data indicated that the Rejuvenate and ABG II Modular-Neck Hip Stems were vulnerable to fretting and corrosion at the modular-neck junction. According to court documents, the metal hip stems were brought to market under the FDA’s 510(k) clearance program, which allows a medical device to come to market without the benefit of clinical trials if a manufacturer can show that its design is “substantially equivalent” to a product already approved by the agency.
According to Stryker, fretting and corrosion of the Rejuvenate and ABG II stems places recipients at risk for adverse local tissue reactions, pain and swelling. In addition, the company advised all patients fitted with a recalled component to undergo medical screening to ensure it is working properly, even if they have not experienced any symptoms that would suggest a problem with their implant.*
Since the recall was announced, court documents indicate more than 2,050 Stryker hip lawsuits have been filed on behalf of Rejuvenate and ABG II hip stem recipients in a multicounty litigation underway in New Jersey’s Bergen County Superior Court. All of these lawsuits similarly allege that the defective nature of the Rejuvenate and ABG II hip stems caused recipients to suffer chronic pain, metallosis, osteolysis, tissue necrosis, and other complications that resulted in premature failure of their hip implant. Bernstein Liebhard LLP is actively filing claims in this proceeding. (In Re Stryker Rejuvenate Hip Stem and the ABG II Modular Hip Stem Litigation, No. 296)
According to court documents, at least 1,692 additional Stryker recall claims that make similar allegations are pending in a federal multidistrict litigation that is currently moving forward in U.S. District Court, District of Minnesota. (In re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation, No. 244)
Individuals who were allegedly harmed by Rejuvenate and ABG II hip stems may be eligible to file their own Stryker hip lawsuit. To learn more about the Stryker hip recall, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange for a free, no-obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP